Secukinumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis Secukinumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis

The results of this study provide evidence that the IL-17 inhibitor secukinumab is effective in managing the concomitant features of psoriasis and psoriatic arthritis.The British Journal of Dermatology

Source: Medscape Today Headlines - January 4, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news